C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

Objective: On-treatment levels of high sensitivity C-reactive protein (hsCRP) in statin-treated patients predict plaque progression and the prospective risk of atherosclerotic cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors produce additional LDL-C lowering, r...

Full description

Bibliographic Details
Main Authors: Adam J. Nelson, Rishi Puri, Danielle M. Brennan, Todd J. Anderson, Leslie Cho, Christie M. Ballantyne, John JP. Kastelein, Wolfgang Koenig, Helina Kassahun, Ransi M. Somaratne, Scott M. Wasserman, Steven E. Nissen, Stephen J. Nicholls
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:American Journal of Preventive Cardiology
Subjects:
PCSK9 inhibitor
Atherosclerosis
C-reactive protein
Intravascular imaging
IVUS
Online Access:http://www.sciencedirect.com/science/article/pii/S266666772030091X

Internet

http://www.sciencedirect.com/science/article/pii/S266666772030091X

Similar Items